|
|
Allergy, Immunology and Rheumatology
Research Funding
(listed alphabetically by Principal Investigator)
2005
Training Program in Pediatric Immunology
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - T32 A107365
Amount: $133,712/yr
Term: 2002-2005
Prevention of Cardiovascular Complications of Pediatric Systemic Lupus Erythematosus: The Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
Principal Investigator: Jennifer Soep, MD
Source: Duke University and National Institutes of Health - N01-AR-2-2265
Term: 2003-2008
2003-2004
Training Program in Pediatric Immunology
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - T32 A107365
Amount: $133,712/yr
Term: 2002-2005
A Multicenter, Rater-Blind, Randomized, Age-Stratified, Parallel-Group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients with Inadequately Controlled Partial Seizures
Principal Investigator: J. Roger Hollister, MD
Source: Novartis Pharmaceuticals Corporation
Term: 2002-2004
Prevention of Cardiovascular Complications of Pediatric Systemic Lupus Erythematosus: The Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
Principal Investigator: Jennifer Soep, MD
Source: Duke University and National Institutes of Health - N01-AR-2-2265
Term: 2003-2008
2001-2002
Training Program in Pediatric Immunology
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - T32 A107365
Amount: $133,712/yr
Term: 2002-2005
CD40-CD154 Interactions in Cryptosporidial Immunity
Principal Investigator: Anthony R. Hayward MD, PhD
Source: National Institutes of Health
Amount: $138,780/yr
Term: 1998-2001
A 12-Week, Double-Blind, Randomized Trial, with 12-Week Open-Label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once-Daily and Naproxen Oral Suspension Administered Twice-Daily in Children with JRA
Principal Investigator: J. Roger Hollister, MD
Source: Boehring Manheim
Term: 2001
A Multicenter, Multinational 8-Month Study of Leflunomide Alone (3 Months) Followed by Leflunomide or Placebo (5 Months) in Patients with Juvenile Rheumatoid Arthritis
Principal Investigator: J. Roger Hollister, MD
Source: Aventis
Term: 2001
A Multicenter, Rater-Blind, Randomized, Age-Stratified, Parallel-Group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients with Inadequately Controlled Partial Seizures
Principal Investigator: J. Roger Hollister, MD
Source: Novartis Pharmaceuticals Corporation
Term: 2002-2004
1999-2000
Cryptosporidia in the Pathogenesis of Sclerosing Cholangitis
Principal Investigator: Anthony R. Hayward MD, PhD
Source: National Institutes of Health
Amount: $75,500/yr
Term: June 1997-May 1999
CD40-CD154 Interactions in Cryptosporidial Immunity
Principal Investigator: Anthony R. Hayward MD, PhD
Source: National Institutes of Health
Amount: $138,780/yr
Term: September 1998-August 2001
Bile Duct Disease in CD154 Deficiency
Principal Investigator: Anthony R. Hayward MD, PhD
Source: March of Dimes Birth Defects Foundation
Amount: $50,000/yr
Term: June 1997-May 1999
Training Program in Pediatric Immunology
Principal Investigator: Anthony R. Hayward MD, PhD
Co-Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health
Amount: $149,516/yr
Term: 1990-2005
|
|
